Real-world impact of education: Treating patients with ipilimumab in a community practice setting

Cancer Management and Research

Volumn 6, Issue 1, 2013, Pages 5-14

  Ledezma, Blanca ^a   Heng, Annie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Angeles Clinic and Research Institute   (United States)

Author keywords

Immunotherapy; Melanoma; Patient education

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; MONOCLONAL ANTIBODY; PLACEBO;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAREGIVER; COMMUNITY CARE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; IMMUNE SYSTEM; IMMUNOTHERAPY; LIVER DISEASE; MELANOMA; MENTAL DISEASE; MOTOR NEUROPATHY; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; NURSING CARE; OVERALL SURVIVAL; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL; PRURITUS; RASH; REVIEW; SENSORY NEUROPATHY; SKIN DISCOLORATION; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 84891128063     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S52543     Document Type: Review

References (26)

1. Korn EL, Liu PY, Lee SJ, Chapman JA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534.
2. Altekruse SF, Kosary CL, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. Available from: http://seer.cancer.gov/csr/1975_2007. Accessed September 22, 2011.
3. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37(5):533-546.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
5. Bristol-Myers Squibb. Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
6. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9(5):587-595.
7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
8. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
9. Bristol-Myers Squibb. Ipilimumab US prescribing information: risk evaluation and mitigation strategy (REMS). 2012. Available from: http://www.yervoy.com/hcp/rems.aspx. Accessed July 12, 2013.
10. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148.
11. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95-106.
12. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5.
13. Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol. 2010;37(5):440-449.
14. Ledezma B. Atypical clinical responses to immunotherapy in patients with advanced melanoma. Poster presented at: Oncology Nursing Society 36th Annual Congress; April 28-May 1, 2011; Boston, MA.
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated, advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11(2):155-164.
16. Bristol-Myers Squibb. Phase 3 trial in subjects with metastatic melanoma comparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab. Available from: http://clinicaltrials.gov/ct2/show/NCT01515189. NLM identifier: NCT01515189. Accessed July 12, 2013.
17. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest. 2007;117(5):1130-1136.
18. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232-2239.
19. National Comprehensive Cancer Network. NCCN guidelines version 2. 2013 updates - melanoma. 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed July 12, 2013.
20. Bristol-Myers Squibb. Study to compare the effect of ipilimumab retreatment with chemotherapy in advanced melanoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01709162. NLM identifier: NCT01709162. Accessed July 12, 2013.
21. Lebbe C, Weber JS, Maio M, et al. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials. Poster presented at: 37th European Society of Medical Oncology (ESMO) Congress; September 28-October 2, 2012; Vienna, Austria.
22. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol. 2009;Chapter 20:Unit 20.11.
23. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
24. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-1397.
25. Ibrahim RA, Berman DM, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29 Suppl:8583.
26. Dummer R, Maio M, Hamid O, et al. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. Poster presented at: Perspectives in Melanoma XIV; September 17-18, 2010; Amsterdam, The Netherlands.